SAN DIEGO, Oct. 31 /PRNewswire/ -- NexBio, Inc. a privately held development-stage biopharmaceutical company located in San Diego, announced today that Dr. David Wurtman, its Vice President of Corporate Development, will present a corporate overview and update at the BIOCOM Investor Conference on November 1, 2007.
NexBio's mission is to save lives, and to improve the quality of life, by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening human viral respiratory diseases. NexBio has received significant financial support through grants and contracts from the National Institutes of Health for development of Fludase(TM), its lead program, a first-in-class broad-spectrum prophylactic and therapeutic agent to potentially address all annual and pandemic variations of influenza, including the Avian IFV H5N1 ("Bird Flu"), as well as parainfluenza. Product candidates in NexBio's pipeline may address additional viral infections, such as RSV.
The company also possesses TOSAP(TM), a novel, elegant, flexible & scalable formulation technology, invented by NexBio scientists, which it uses to make dry-powder microspheres to allow drugs to be delivered by inhalation. TOSAP(TM) is being applied to expand the company's pipeline, and is also being licensed to partners who wish to formulate their own compounds.
NexBio is actively seeking corporate partnerships from companies that have extensive experience in late stage drug development and commercialization, as well as entertaining inquiries from financing sources that may wish to invest in the company.
For more information about NexBio, Inc., please visit http://www.nexbio.com
David Wurtman, M.D., M.B.A
VP, Corporate Development
10665 Sorrento Valley Road
San Diego, CA 92121
Phone: (858) 452-2631
Note: FDA has yet to approve the name Fludase.
|SOURCE NexBio, Inc.|
Copyright©2007 PR Newswire.
All rights reserved